243 results about "Lipidome" patented technology

The invention relates to crop plants comprising novel seed lipid compositions. Provided are both wild type and mutant nucleic acid molecules encoding Brassica fatty acyl-acyl carrier protein (ACP) thioesterase B proteins (FATB) and the proteins as such. Also provided are Brassica plants, tissue and seeds comprising at least three mutant fatB alleles in their genome, whereby the seed oil fatty acid composition or profile is significantly altered.

Disclosed are formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and/or other cells or tissues. Also provided are compositions and uses for cationic lipid compounds of formula (I).

The invention also relates to compositions and uses for stealth lipids of formula (XI).

Also provided are processes for making such compounds, compositions, and formulations, plus methods and uses of such compounds, compositions, and formulations to deliver biologically active agents to cells and/or tissues.

This invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R¹-R³, n, p, L₁ and L₂ are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

A cosmetic composition comprising (A) a first structured and adhesive film-forming fatty phase comprising (i) one or more lipidic components that are mutually compatible with one another when liquefied; (ii) at least one adhesive film-forming agent; and (iii) at least one lipophilic structuring agent in an amount effective to retain a second fatty phase entrapped in said cosmetic composition prior to application on mammalian keratinous tissue; and (B) a second fatty phase comprising at least one non-volatile lipidic component wherein said second fatty phase (B) is incompatible with said first structured and adhesive film-forming fatty phase (A) and said second fatty phase (B) is entrapped in said composition where upon application of said composition to mammalian keratinous tissue, said second fatty phase (B) readily separates from said composition to form a barrier layer over said first structured and adhesive film-forming fatty phase (A) and wherein said composition is substantially free of surfactants such that separation of said second fatty phase (B) from said composition is not prevented following application of said composition.

A liposome composition and method for delivery of a nucleic acid in vivo or ex vivo is described. The liposomes in the composition are comprised of (i) a cationic lipid and (ii) a lipid joined to a hydrophilic polymer by a releasable linkage. The liposomes are associated with a nucleic acid for delivery to a cell.

Lipid assemblies, such as liposomes, comprising transfection enhancer elements (TEE's), which are complexed with the lipid assemblies by means of ionic interactions, or lipids incorporating such TEE's are disclosed for enhancing the fusogenicity of the lipid assemblies. The TEE's have the formula:

hydrophobic moiety-pH sensitive hydrophilic moiety  (II)

The pH sensitive hydrophilic moiety of each TEE is a weak acid having a pka of between 2 and 6 or a zwitterionic structure comprising a combination of acidic groups with weak bases having a pKa of between 3 and 8. Lipids incorporating one or more such TEEs have the formula (I):

Lipid moiety-[Hydrophobic moiety-pH sensitive hydrophilic moiety]  (I)

The invention discloses a method for simultaneous extraction and analysis of a metabolite group and a lipid group in microtissue. The method comprises the following steps: freeze drying to-be-analyzed microtissue, accurately weighing 1 to 25 mg of the freeze-dried microtissue and adding solvents like methanol (MeOH), methyl tert butyl ether (MTBE) and water in certain proportion for extraction; allowing a solution obtained after completion of extraction to be divided into two layers, wherein an upper layer mainly contains nonpolar metabolites and lipids, and the lower layer mainly comprises polar and medium-polar metabolites; and subjecting the upper-layer solution and the lower-layer solution to mixing in proportion and freeze-drying, then carrying out redissolving and then metabonomical analysis based on liquid chromatography-mass spectrometry, subjecting the upper-layer solution to freeze-drying and then to redissolving and carrying out lipidomical analysis based on liquid chromatography-mass spectrometry. The method has the following advantages: metabolites and lipids are extracted as many as possible through one extraction of a small amount of tissue, and through metabonomical and lipidomical analysis, the amount of a tissue sample is saved, which benefits other biochemical analysis of the tissue sample.

The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.

The invention provides a liposome composition for delivering high pay-load of a therapeutic agent to neovascularization sites of the eyes in a patient in need thereof. The liposome composition for entrapping the therapeutic agent comprises a particle forming component composed of a variety of vesicle-forming lipids, and an agent-carrying component able to form a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction; wherein the liposome composition comprising the therapeutic agent has a mean particle diameter of about 30 to 200 nm and may accumulate at the neovascularization sites of the eyes 24 hours after the intravenous administration of the liposome composition comprising the therapeutic agent to the patient. A method for delivering the therapeutic agent to the eyes in a patient with this liposome composition is also provided

A composition is for feeding aquacultural prey organisms such as Artemia and rotifiers, comprising a lipid component comprising at least 25 wt % of phospholipids and providing a DHA content of at least 30 wt %. The lipid component is preferably derived from marine organisms such as fishineal, phytoplankton or zoo plankton biomass. The composition is used for providing prey organisms having a high content of highly-unsaturated fatty acids (HUFAs) suitable for aquaculture of fish including halibut, turbot, bass and crustaceans and molluses.

The present invention relates generally to methods for detecting complications, or abnormal conditions occurring during pregnancy, including placental abnormalities, eclampsia, or preelcampsia. The present invention comprises the steps of obtaining a sample from a patient, assaying the specimen to determine the level of bioactive lipids and comparing levels in the sample to control values or levels in normal samples, and correlating alterations to disease. The invention includes measuring panels of bioactive lipids to screen patients for disease and to monitor the progress of disease for diagnostic or therapeutic purposes.

The present application provides a composition comprising (1) a lipid composition comprising an ionizable amino lipid and a quaternary amine compound and (2) a polynucleotide. The present application also provides a composition comprising (1) a lipid composition comprising an asymmetric phospholipid, an ionizable amino lipid, and optionally a quaternary amine compound and (2) a polynucleotide, wherein the composition is formulated for intratumoral delivery of the polynucleotide. The present application further provides pharmaceutical compositions for intratumoral delivery comprising (1) a lipid composition comprising a compound of formula (I) and (2) therapeutic agent or a polynucleotide encoding the therapeutic agent, e.g., an mRNA encoding a therapeutic protein or a fragment thereof. Further provided is a method of increasing retention of a polynucleotide in a tumor tissue by using such a composition.

The invention discloses a network dynamic searching method for lipid metabolism. The method is based on stable isotope labeling assisted lipidomics and combined with non-target isotope isomer screening. The network dynamic searching method is characterized in that stable isotope labeling cell, animal or human experiments, high resolution UHPLC-MS lipidomics analysis and the non-target isotope isomer screening are combined; the dynamic metabolism processes, such as synthesis, conversion and decomposition of lipid molecules in the lipid metabolism fingerprint acquisition can be captured while the lipid metabolism fingerprint in a static state is acquired. The network dynamic searching method for the lipid metabolism has high molecule specificity and extensive network coverage capability; the method is repeatable, steady and reliable. The method develops a new idea for deeply searching lipid metabolism and aims to gain more profound and comprehensive understanding in pathological process, physiological process and metabolism perturbation in the biosystem.

The present invention relates to a lipid nanoparticle system comprising a lipid component, a cationic surfactant, a non-ionic surfactant, a polysaccharide and, optionally, a positively charged peptide, useful for the release of pharmacologically active molecules, and especially for transfecting genetic material into cells and/or tissues. It also relates to methods for obtaining nanoparticles, to pharmaceutical compositions comprising it, as well as to the use thereof in gene therapy.

The invention discloses a large-scale blood plasma sphingolipid profile analysis method based on liquid chromatography-mass spectrometry combination, which is characterized in that sphingolipid in blood plasma is extracted by double-phase extraction with methyl tertiary butyl ether/methanol/water (MTBE/MeOH/H2O) combined with mild basic hydrolysis. Then rapid semi-quantitative analysis is realized within 15 min by combination of ultra-high performance liquid chromatography-electro-spray ionization-mass spectrometry. In the invention, the MTBE/MeOH/H2O extraction system is simple, rapid, and easy to operate, has less protein interference in the extract, and has good repeatability; interference of high-abundance phospholipid and glyceride in the lipid group is eliminated by hydrolysis; ion inhibition is reduced; therefore, the purpose of detecting low-abundance sphingolipid with high sensitivity is achieved. With the high resolution separation capability of subsequent ultra-high performance liquid chromatography (UHPLC) and the specificity of MRM, effective distinguishing of isomers is realized, and the introduction of complex isotope correction during quantification is avoided, which makes the method more rapid and accurate.

The invention features methods and apparatus for producing lipid nanoparticles. Methods of the invention include injecting a lipid solution into an aqueous solution at an automated rate (e.g., a rate controlled by a servo pump). The invention provides methods and apparatus for making lipid nanoparticles possessing a wide range of lipid components and hydrophilic encapsulants, including nucleic acids (e.g., mRNA). Also provided are nanoparticles and compositions thereof made by methods and apparatus of the invention.